S&P 500   5,081.91 (+0.24%)
DOW   38,922.99 (-0.07%)
QQQ   437.13 (+0.43%)
AAPL   179.76 (-0.92%)
MSFT   408.32 (+0.15%)
META   486.70 (+0.55%)
GOOGL   136.91 (+0.39%)
AMZN   174.77 (+0.93%)
TSLA   199.96 (-1.03%)
NVDA   789.20 (+1.62%)
NIO   5.65 (+4.05%)
AMD   188.75 (+6.92%)
BABA   74.10 (-0.66%)
T   16.97 (+0.06%)
F   12.38 (+0.65%)
MU   89.49 (-0.25%)
CGC   3.29 (-2.08%)
GE   155.72 (+0.07%)
DIS   111.36 (+0.51%)
AMC   4.28 (-14.23%)
PFE   26.78 (-0.96%)
PYPL   60.19 (-0.10%)
XOM   104.66 (+0.33%)
S&P 500   5,081.91 (+0.24%)
DOW   38,922.99 (-0.07%)
QQQ   437.13 (+0.43%)
AAPL   179.76 (-0.92%)
MSFT   408.32 (+0.15%)
META   486.70 (+0.55%)
GOOGL   136.91 (+0.39%)
AMZN   174.77 (+0.93%)
TSLA   199.96 (-1.03%)
NVDA   789.20 (+1.62%)
NIO   5.65 (+4.05%)
AMD   188.75 (+6.92%)
BABA   74.10 (-0.66%)
T   16.97 (+0.06%)
F   12.38 (+0.65%)
MU   89.49 (-0.25%)
CGC   3.29 (-2.08%)
GE   155.72 (+0.07%)
DIS   111.36 (+0.51%)
AMC   4.28 (-14.23%)
PFE   26.78 (-0.96%)
PYPL   60.19 (-0.10%)
XOM   104.66 (+0.33%)
S&P 500   5,081.91 (+0.24%)
DOW   38,922.99 (-0.07%)
QQQ   437.13 (+0.43%)
AAPL   179.76 (-0.92%)
MSFT   408.32 (+0.15%)
META   486.70 (+0.55%)
GOOGL   136.91 (+0.39%)
AMZN   174.77 (+0.93%)
TSLA   199.96 (-1.03%)
NVDA   789.20 (+1.62%)
NIO   5.65 (+4.05%)
AMD   188.75 (+6.92%)
BABA   74.10 (-0.66%)
T   16.97 (+0.06%)
F   12.38 (+0.65%)
MU   89.49 (-0.25%)
CGC   3.29 (-2.08%)
GE   155.72 (+0.07%)
DIS   111.36 (+0.51%)
AMC   4.28 (-14.23%)
PFE   26.78 (-0.96%)
PYPL   60.19 (-0.10%)
XOM   104.66 (+0.33%)
S&P 500   5,081.91 (+0.24%)
DOW   38,922.99 (-0.07%)
QQQ   437.13 (+0.43%)
AAPL   179.76 (-0.92%)
MSFT   408.32 (+0.15%)
META   486.70 (+0.55%)
GOOGL   136.91 (+0.39%)
AMZN   174.77 (+0.93%)
TSLA   199.96 (-1.03%)
NVDA   789.20 (+1.62%)
NIO   5.65 (+4.05%)
AMD   188.75 (+6.92%)
BABA   74.10 (-0.66%)
T   16.97 (+0.06%)
F   12.38 (+0.65%)
MU   89.49 (-0.25%)
CGC   3.29 (-2.08%)
GE   155.72 (+0.07%)
DIS   111.36 (+0.51%)
AMC   4.28 (-14.23%)
PFE   26.78 (-0.96%)
PYPL   60.19 (-0.10%)
XOM   104.66 (+0.33%)
NASDAQ:ARWR

Arrowhead Pharmaceuticals (ARWR) Stock Price, News & Analysis

$32.86
-1.14 (-3.35%)
(As of 12:45 PM ET)
Today's Range
$32.50
$35.36
50-Day Range
$27.83
$39.48
52-Week Range
$20.67
$42.48
Volume
1.07 million shs
Average Volume
1.75 million shs
Market Capitalization
$4.07 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$51.25

Arrowhead Pharmaceuticals MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.62 Rating Score
Upside/​Downside
50.7% Upside
$51.25 Price Target
Short Interest
Bearish
7.08% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-2.55
Upright™ Environmental Score
News Sentiment
1.31mentions of Arrowhead Pharmaceuticals in the last 14 days
Based on 9 Articles This Week
Insider Trading
Selling Shares
$5.90 M Sold Last Quarter
Proj. Earnings Growth
Growing
From ($2.70) to ($2.53) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

4.42 out of 5 stars

Medical Sector

112th out of 958 stocks

Pharmaceutical Preparations Industry

40th out of 450 stocks


ARWR stock logo

About Arrowhead Pharmaceuticals Stock (NASDAQ:ARWR)

Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes Plozasiran, which is in Phase 2b and one Phase 3 clinical trial to treat hypertriglyceridemia, mixed dyslipidemia, and chylomicronemia syndrome; Zodasiran that is in Phase 2b clinical trial for the treatment of dyslipidemia and hypertriglyceridemia; ARO-PNPLA3, which is in Phase 1 clinical trial to treat patients with non-alcoholic steatohepatitis; ARO-RAGE that is in Phase 1/2a clinical trial to treat inflammatory pulmonary conditions; and ARO-MUC5AC, which is in Phase 1/2a clinical trial to treat muco-obstructive pulmonary diseases. It also develops ARO-MMP7 that is in Phase 1/2a clinical trial for treatment of idiopathic pulmonary fibrosis; ARO-DUX4 for the treatment of facioscapulohumeral muscular dystrophy; ARO-SOD1 for the potential treatment of amyotrophic lateral sclerosis; and ARO-C3, which is in Phase 1/2a clinical trial for the treatment of patients with various complement mediated or complement associated renal diseases. In addition, the company is involved in the development of JNJ-3989, which is in Phase 2 clinical trial to treat chronic hepatitis B virus infection; Olpasiran that is in Phase 3 clinical trial to reduce the production of apolipoprotein A; GSK-4532990 that is in phase 2 clinical trial to treat liver diseases; HZN-457, which is in phase 1 clinical trial to treat uncontrolled gout; and Fazirsiran that is in Phase 3 clinical trial for the treatment for liver disease associated with alpha-1 antitrypsin deficiency. Arrowhead Pharmaceuticals, Inc. has license and research collaboration agreements with Janssen Pharmaceuticals, Inc.; Takeda Pharmaceutical Company Limited; Horizon Therapeutics Ireland DAC; Amgen Inc.; and Glaxosmithkline Intellectual Property (No. 3) Limited. The company was founded in 2003 and is headquartered in Pasadena, California.

ARWR Stock Price History

ARWR Stock News Headlines

The Strategic Gold Play You Haven't Heard About
Experts recommend adding gold to your portfolio, but in what form? Some savvy investors are now rejecting coins and mining stocks in favor of a unique gold investment alternative. It holds explosive growth potential similar to a junior gold stock -- but with less risk exposure.
ARWR Mar 2024 30.000 call
Rare Earth Elements: The Workhorse of The Tech Revolution
They're the most underrated yet crucial elements of technology. From renewable energy to military defense, Rare Earths are essential pieces of modern technology. Global superpowers and savvy investors are quickly learning just how valuable they truly are.
Q1 2024 Arrowhead Pharmaceuticals Inc Earnings Call
Arrowhead Pharmaceuticals Inc Insider Sells Shares
Arrowhead Pharma Gains 6%, Prices $450 Mln Offering Of Shares
See More Headlines
Receive ARWR Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Arrowhead Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
2/06/2024
Today
2/29/2024
Next Earnings (Estimated)
5/07/2024
Fiscal Year End
9/30/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:ARWR
Employees
525
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$51.25
High Stock Price Target
$90.00
Low Stock Price Target
$27.00
Potential Upside/Downside
+50.7%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.62
Research Coverage
13 Analysts

Profitability

Net Income
$-205,270,000.00
Net Margins
-163.32%
Pretax Margin
-166.93%

Debt

Sales & Book Value

Annual Sales
$240.74 million
Book Value
$1.40 per share

Miscellaneous

Free Float
118,322,000
Market Cap
$4.21 billion
Optionable
Optionable
Beta
0.78
12 Stocks Corporate Insiders are Abandoning Cover

If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know?

Get This Free Report

Key Executives

  • Dr. Christopher R. Anzalone Ph.D. (Age 55)
    CEO, President & Director
    Comp: $1.6M
  • Mr. Kenneth A. MyszkowskiMr. Kenneth A. Myszkowski (Age 58)
    Chief Financial Officer
    Comp: $834.34k
  • Mr. Patrick O'Brien J.D. (Age 60)
    PharmD, COO, General Counsel & Secretary
    Comp: $835.14k
  • Dr. James C. Hamilton M.D. (Age 46)
    MBA, Chief of Discovery & Translational Medicine
    Comp: $762.14k
  • Dr. Mark M. Davis Ph.D.
    Founder and Founder & Director of Insert Therapeutics Inc & Calando
  • Dr. Vincent Anzalone CFA
    Head of Investor Relations & VP
  • Mr. Howard Lovy
    Director of Communications
  • Dr. Bruce D. Given M.D. (Age 70)
    Chief Medical Scientist
    Comp: $486.31k
  • Dr. Mark Seefeld (Age 70)
    Head of Toxicology & VP
  • Ms. Tracie OliverMs. Tracie Oliver (Age 62)
    Chief Commercial Officer
    Comp: $449.58k














ARWR Stock Analysis - Frequently Asked Questions

Should I buy or sell Arrowhead Pharmaceuticals stock right now?

13 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Arrowhead Pharmaceuticals in the last year. There are currently 5 hold ratings and 8 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" ARWR shares.
View ARWR analyst ratings
or view top-rated stocks.

What is Arrowhead Pharmaceuticals' stock price target for 2024?

13 Wall Street research analysts have issued 12-month target prices for Arrowhead Pharmaceuticals' shares. Their ARWR share price targets range from $27.00 to $90.00. On average, they predict the company's share price to reach $51.25 in the next twelve months. This suggests a possible upside of 50.7% from the stock's current price.
View analysts price targets for ARWR
or view top-rated stocks among Wall Street analysts.

How have ARWR shares performed in 2024?

Arrowhead Pharmaceuticals' stock was trading at $30.60 on January 1st, 2024. Since then, ARWR stock has increased by 11.1% and is now trading at $34.00.
View the best growth stocks for 2024 here
.

Are investors shorting Arrowhead Pharmaceuticals?

Arrowhead Pharmaceuticals saw a increase in short interest in February. As of February 15th, there was short interest totaling 8,770,000 shares, an increase of 13.6% from the January 31st total of 7,720,000 shares. Based on an average daily volume of 1,620,000 shares, the short-interest ratio is currently 5.4 days.
View Arrowhead Pharmaceuticals' Short Interest
.

When is Arrowhead Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 7th 2024.
View our ARWR earnings forecast
.

How were Arrowhead Pharmaceuticals' earnings last quarter?

Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) posted its quarterly earnings results on Tuesday, February, 6th. The biotechnology company reported ($1.24) EPS for the quarter, missing analysts' consensus estimates of ($0.78) by $0.46. The biotechnology company had revenue of $3.55 million for the quarter, compared to analysts' expectations of $35.60 million. Arrowhead Pharmaceuticals had a negative net margin of 163.32% and a negative trailing twelve-month return on equity of 90.77%. The business's quarterly revenue was down 94.3% compared to the same quarter last year. During the same quarter in the previous year, the firm earned ($0.39) earnings per share.

What other stocks do shareholders of Arrowhead Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Arrowhead Pharmaceuticals investors own include Bellicum Pharmaceuticals (BLCM), NVIDIA (NVDA), AbbVie (ABBV), Micron Technology (MU), Alibaba Group (BABA), Alliance Resource Partners (ARLP), Bank of America (BAC), Tesla (TSLA), Salesforce (CRM) and Advanced Micro Devices (AMD).

Who are Arrowhead Pharmaceuticals' major shareholders?

Arrowhead Pharmaceuticals' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Vanguard Group Inc. (8.61%), Norges Bank (1.07%), Capital International Investors (1.03%), Northern Trust Corp (0.99%), Avoro Capital Advisors LLC (0.91%) and Goldman Sachs Group Inc. (0.86%). Insiders that own company stock include Adeoye Y Olukotun, Backer Marianne De, Christopher Richard Anzalone, Douglas B Given, Douglas B Given, James C Hamilton, James Hassard, Kenneth Allen Myszkowski, Martin Javier San, Patrick O'brien, Tracie Oliver, Victoria Vakiener and William D Waddill.
View institutional ownership trends
.

How do I buy shares of Arrowhead Pharmaceuticals?

Shares of ARWR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:ARWR) was last updated on 2/29/2024 by MarketBeat.com Staff